Monthly Archives: April 2018

Now Introducing the MNGenome®

MNG is proud to announce the launch of the MNGenome®. This new test sequences the entire human genome, making it our most comprehensive clinical diagnostic test ever. The MNGenome® provides greater sensitivity than whole exome sequencing, since approximately 20% of known pathogenic variants are outside the exon boundaries. The MNGenome® is a comprehensive approach to diagnosis when faced with challenging phenotypes, and no diagnosis with CMA and whole exome sequencing.

To read the full press release, click here.


MNG Expands Global Reach with Several New Distributors

MNG Laboratories is pleased to announce the signing of several key international distributor agreements in Asia, Latin America and Eastern Europe. MNG now has active distributors representing our extensive menu of over 500 neurogenetic and biochemical tests in Mexico, Hong Kong, Turkey and Chile. Each distributor was chosen for their clinical expertise, excellent customer service, and technical leadership in their respective markets.
“This is just the start of MNG’s expansion strategy for global markets since we brought on dedicated business development talent to address this market opportunity late in 2017,” noted MNG’s President & CEO Terry Conrad. “We have additional pending agreements in different phases of development across the globe and are active in seeking additional partnerships in the Pharmaceutical, Biotech and University research arenas. MNG has a leadership position in neurogenetic and complex biochemical testing and our products and experience are trusted by research and development interests who are focused in neurology.”

To read the full press release, click here.